LIFERIVER(SH:688317)2025-02-27 07:50Financial Performance - Total revenue for 2024 was RMB 183.40 million, a decrease of 33.15% compared to RMB 274.33 million in the previous year[4] - Net profit attributable to the parent company was a loss of RMB 127.51 million, a reduction in loss of RMB 9.35 million year-on-year[6] - Basic earnings per share were -RMB 0.67, compared to -RMB 0.71 in the previous year[4] - The net profit for the reporting period was negative due to a decline in operating income and impairment provisions for inventory and fixed assets[7] Assets and Equity - Total assets at the end of the reporting period were RMB 3,791.41 million, down 6.94% from the beginning of the period[6] - Equity attributable to the parent company decreased to RMB 3,636.84 million, a decline of 4.92%[5] Business Strategy - The company continued to enhance investment in product research and development, expanding new product lines and marketing in respiratory diseases, gynecological tumors, and liver diseases[6] - The decline in total revenue was primarily due to decreased sales of self-developed molecular diagnostic reagents and equipment[9] - The company is actively exploring international markets to improve its operational efficiency and profitability[6] Financial Reporting - The financial data presented is preliminary and subject to final audit in the annual report[10]